Abbott completes $105/share cash acquisition of Exact Sciences, expanding cancer diagnostics

ABBOTT LABORATORIES

Abbott completed acquisition of Exact Sciences for $105/share cash; Exact becomes wholly owned subsidiary.
Exact Sciences last trading day was March 20, 2026; shares converted to $105 cash.
Deal adds Cologuard, Oncotype DX, Oncodetect, Cancerguard cancer screening diagnostics.
Abbott becomes leader in $60B U.S. cancer screening and precision oncology diagnostics market.
Acquisition adds growth vertical to Abbott's high-single-digit growth expectations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.